Back to search results

Studying GLP-1 Production and Type 2 Diabetes Risk

This study is looking at how a specific genetic difference (called rs7903146) affects the body's production of GLP-1 (Glucagon-Like Peptide-1), a hormone important for blood sugar control. Researchers want to understand if this genetic difference influences how GLP-1 is made in the pancreas, especially in people who have a higher risk for type 2 diabetes. You would receive either Exendin 9-39, which blocks GLP-1's action, or a saline (saltwater) infusion. The main goal is to see how these infusions change your fasting blood sugar and glucagon levels. This study is for people aged 25 to 70 who have specific genetic variations (TT or CC genotype at rs7903146) and do not have advanced type 2 diabetes.

Study design
This is an interventional study planning to enroll 80 participants. It compares the effects of Exendin 9-39 to a saline infusion.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary measurements for changes in glucose and glucagon are taken between -30 minutes and 0 minutes of each study day.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06972407

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

Not Yet Recruiting
PHASE2Ages 25–70InterventionalBasic science
Mayo Clinic
~80 participants
Updated 2026-01-30 on ClinicalTrials.gov
What's tested:Exendin 9-39Saline

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in fasting glucose
Measured over Change in average glucose concentration between -30 min and 0 min of each study day (saline day vs. exendin 9-39 day)
+1 more outcome measured

Conditions

Genetic Predisposition
Type2diabetes

Explore related trials

Type 2 Diabetes MellitusTranscription Factor 7-Like 2

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Adrian Vella, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Adrian Vella, MD
[email protected]
507-255-6515
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects with the TT or CC genotype at rs7903146

What this trial measures

  • Change in fasting glucoseChange in average glucose concentration between -30 min and 0 min of each study day (saline day vs. exendin 9-39 day)

    comparison of fasting glucose during saline vs. exendin 9-39 infusion

  • Change in fasting glucagonChange in average glucagon concentration between -30 min and 0 min of each study day (saline day vs. exendin 9-39 day)

    comparison of fasting glucagon during saline vs. exendin 9-39 infusion